[Treatment of cerebrovascular insufficiency. A double blind trial of Cetal retard against cinnarizine (author's transl)].
The results of a double blind trial in a total of 54 outpatients with cerebrovascular insufficiency are reported. With reference to objective test criteria (flicker frequency analysis and reaction test) and the change in the existing symptoms of this clinical picture the behavior of a new preparation, Cetal retard, was compared with the well-known drug (cinnarizine) with regard to the therapeutic efficacy on these symptoms. Although a therapeutic success was demonstrable in both groups after 21 days, Cetal retard was found to be significantly better in a number of the criteria tested.
D000368:Aged; D001288:Attention / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002936:Cinnarizine / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005425:Flicker Fusion / Q000187:drug effects; D006261:Headache / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011930:Reaction Time / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy; D014748:Vinca Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D010879:Piperazines; D014748:Vinca Alkaloids; D002936:Cinnarizine
Therapie der zerebrovaskulären Insuffizienz. Doppelblindprüfung von Cetal retard gegen Cinnarizin.